二、董事会会议审议情况 （一）审议通过了《关于聘任副总经理的议案》 为充实专业技术人员，优化公司业务管理，经公司总经理提名、提名委员会 资格审查、独立董事发表同意的独立意见、公司董事会审议通过，公司同意聘任 WENYU ZHANG（张文宇）先生为公司副总经理，任期自第五届董事会第十七次会 议审议通过之日起至第五届董事会届满之日止。 具体内容详见同日在巨潮资讯网（www.cninfo.com.cn）上披露的《关于聘 任副总经理的公告》。 证券代码：002581 证券简称：未名医药 公告编号：2023-058 山东未名生物医药股份有限公司 第五届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东未名生物医药股份有限公司(以下简称"公司")第五届董事会第十七次 会议于 2023 年 8 月 14 日上午 10 时以通讯方式召开。应参加表决董事 11 名，实 际参加表决董事 11 人，分别为：岳家霖、刘文俊、黄桂源、郑喆、于秀媛、于 文杰、肖杰、张荣富、刘洋、夏阳、赵辉。董事会会议通知已于 2023 年 8 月 ...

山东未名生物医药股份有限公司 独立董事关于第五届董事会第十七次会议相关议案 的独立意见 根据《关于在上市公司建立独立董事制度的指导意见》、深圳证券交易所《上 市公司规范运作指引》及山东未名生物医药股份有限公司（以下简称"公司"） 《独立董事工作制度》等相关法律法规、规章制度的有关规定，我们作为公司的 独立董事，现就公司第五届董事会第十七次会议审议的议案内容进行了认真审议， 并发表如下独立意见： 我们认为本次聘任副总经理的提名、审议、表决程序符合有关法律法规和公 司《章程》的规定，根据 WENYU ZHANG（张文宇）先生的个人简历、工作经历等 情况，其任职资格、教育背景、专业能力能够胜任所聘岗位职责的要求；未发现 其存在《公司法》中规定的不得担任公司高级管理人员的情况，以及被中国证监 会确定为市场禁入者之现象，不存在被深圳证券交易所公开认定不适合担任上市 公司高级管理人员的情况，也未曾受到过中国证监会和深圳证券交易所的任何处 罚和惩戒。同意聘任 WENYU ZHANG（张文宇）先生为公司副总经理。 1、关于聘任副总经理的独立意见 （此页无正文，为山东未名生物医药股份有限公司独立董事关于第五届董事会第 十七次会 ...

一、召开会议的基本情况 山东未名生物医药股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 证券代码：002581 证券简称：未名医药 公告编号：2023-064 （一）会议召集人：公司董事会 （2）通过互联网投票系统进行网络投票的时间：2023 年 9 月6 日 9:15-15:00。 （四）会议召开方式：现场投票与网络投票相结合的方式 公 司 将 通 过 深 圳 证 券 交 易 所 交 易 系 统 和 互 联 网 投 票 系 统 (http://wltp.cninfo.com.cn)向全体股东提供网络形式的投票平台，公司股东 可以在网络投票时间内通过上述系统行使表决权。 公司股东应选择现场投票、网络投票中的一种方式,如果同一表决权出现重 复投票表决的,以第一次有效投票表决结果为准。 （五）股权登记日：2023 年 9 月 1 日 （六）会议出席对象 （二）会议召开的合法、合规性：公司 2023 年第二次临时股东大会会议的 召集、召开符合《公司法》等法律、法规、规范性文件和《公司章程》的有关规 定。 ...

证券代码：002581 证券简称：未名医药 公告编号：2023-059 山东未名生物医药股份有限公司 第五届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东未名生物医药股份有限公司(以下简称"公司")第五届监事会第十一次 会议于 2023 年 8 月 14 日上午 10:30 时以通讯方式召开。应参加表决监事 3 名， 实际参加表决监事 3 人，分别为：刘铁夫、闫雪明、柯莹。监事会会议通知已于 2023 年 8 月 11 日以通讯方式发出，会议由公司监事会主席刘铁夫先生主持。本 次监事会的召集和召开符合国家有关法律、法规、《监事会议事规则》及《公司 章程》的规定。本次会议逐项审议了如下议案： 二、监事会会议审议情况 （一）审议通过了《关于签署<山东未名生物医药产业园投资建设和资产回 购协议>暨接受关联方担保的议案》 为进一步完善公司产业布局，扩大公司主营业务产品的产能规模，提高市场 份额与综合竞争力，充分发挥合作各方优势和效应，公司与淄博市张店区工业和 信息化局签署《行政服务协议》，在淄博市张店经济开发 ...

证券代码：002581 证券简称：未名医药 公告编号：2023-063 山东未名生物医药股份有限公司 关于变更控股子公司董事、法定代表人等的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）于 2023 年 8 月 14 日 召开了第五届董事会第十七次会议，审议通过了《关于变更控股子公司董事、法 定代表人等的议案》。为优化公司管理结构，依据公司相关规定，公司董事会同 意将公司控股子公司天津未名生物医药有限公司（以下简称"天津未名"）董事、 法定代表人由岳家霖先生变更为张旭东先生，董事长由岳家霖先生变更为徐隽雄 先生，总经理由徐隽雄先生变更为张旭东先生。山东未名天源生物科技有限公司 （以下简称"未名天源"）将董事会制度变更为执行董事制度，由徐隽雄先生担 任执行董事。同时，公司董事会同意天津未名、未名天源根据上述变更事项修订 《公司章程》相应内容。 本次变更控股子公司董事、法定代表人等的事项无需提交公司股东大会审议， 变更内容和章程条款等的修订最终以市场监督管理部门的核准结果为准。现将有 关事项公告如下： 一、 ...

证券代码：002581 证券简称：未名医药 公告编号：2023-060 山东未名生物医药股份有限公司 关于聘任副总经理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 山东未名生物医药股份有限公司（以下简称"公司"）于 2023 年 8 月 14 日 召开了第五届董事会第十七次会议，审议通过了《关于聘任副总经理的议案》。 为充实专业技术人员，优化公司业务管理，经公司总经理提名、提名委员会资格 审查、独立董事发表同意的独立意见、公司董事会审议通过，公司同意聘任 WENYU ZHANG（张文宇）先生为公司副总经理，任期自第五届董事会第十七次会议审议 通过之日起至第五届董事会届满之日止。 董事会 2023 年 8 月 16 日 简历 WENYU ZHANG（张文宇），男，1955 年 5 月出生，美国国籍，医学/药理学博 士，已取得中华人民共和国外国人永久居留身份证。曾就职美国葛兰素史克 （GSK）制药公司全球临床研究总监、美国威泰尔医疗中国区总经理、法国赛 诺菲制药公司亚太研发中心临床项目拓展总监。2012 年 8 月入职未名医药， 现任未名医药首席科学家 ...

证券代码：002581 证券简称：未名医药 公告编号：2023-061 山东未名生物医药股份有限公司 关于签署《山东未名生物医药产业园投资建设和资产回购 协议》暨接受关联方担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 重要提示： 1、本次投资建设事项，是基于公司战略发展的需要及对行业市场前景的判 断，鉴于项目实施需要经历一定的时间周期，期间的实施进展以及未来的实际 经营状况与潜在收益可能受到宏观经济政策调整、行业周期波动、市场竞争加 剧、技术更新迭代、产品需求变化以及项目运营管理等诸多不确定因素影响， 同时，本次投资建设事项尚需通过相关行政主管部门审批等一系列程序，项目 完成后还可能面临市场及技术方面的风险，存在项目建设进度或最终实现收益 不达预期的风险。 2、本次资产回购事项，如因国家或地方有关政策调整、资产权属变更等实 施条件发生变化，导致资产回购事项不能如期进行，本协议的履行可能存在延 期、变更或终止的风险。 3、因山东未名生物医药产业园一期尚未建设完毕，公司无法预计最终回购 金额，具体回购金额以年度会计师审计结果为准。 4、本次投资建设 ...

证券代码：002581 证券简称：未名医药 公告编号：2023-062 山东未名生物医药股份有限公司 关于续聘 2023 年度会计师事务所的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，不存在虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、山东未名生物医药股份有限公司(以下简称"公司")2022 年度财务审计 报告的审计意见类型为带强调事项段保留意见。 2、本次拟续聘的会计师事务所名称为深圳广深会计师事务所（普通合伙） （以下简称"深圳广深会计师事务所"），不涉及变更会计师事务所的情形。 3、公司审计委员会、独立董事、董事会、监事会对本次拟续聘会计师事务 所事项无异议。本事项尚需提交公司股东大会审议。 公司于 2023 年 8 月 14 日召开第五届董事会第十七次会议、第五届监事会第 十一次会议，审议通过《关于续聘 2023 年度会计师事务所的议案》，同意拟续 聘深圳广深会计师事务所为公司 2023 年度审计机构，负责公司 2023 年度财务报 表和内部控制审计工作。本议案尚需提交公司股东大会审议。现将有关事项公告 如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 1、基本信息 ...

山东未名生物医药股份有限公司独立董事 关于公司第五届董事会第十七次会议相关议案的事前认可意见 综上，我们同意公司就该事项接受关联方担保，并同意将《关于签署<山东 未名生物医药产业园投资建设和资产回购协议>暨接受关联方担保的议案》提交 公司第五届董事会第十七次会议审议。 二、关于拟续聘 2023 年度会计师事务所的事前认可意见 我们对续聘 2023 年度会计师事务所表示认可。经核查，深圳广深会计师事 务所具有证券、期货相关业务执业资格，具备为上市公司提供财务报告审计和内 部控制审计服务的经验和能力，能够满足公司财务报告审计和内部控制审计工作 要求。本次拟续聘会计师事务所事项是基于公司业务发展需要，不存在损害公司 及其他股东利益、尤其是中小股东利益。 因此，我们一致同意将该议案提交第五届董事会第十七次会议审议。 （以下无正文） 我们作为山东未名生物医药股份有限公司（以下简称"公司"）的独立董事， 按照中国证监会《关于在上市公司建立独立董事制度的指导意见》、《深圳证券交 易所上市公司规范运作指引》的要求和《公司章程》、《独立董事工作制度》所赋 予的职责，对公司第五届董事会第十七次会议审议的相关议案进行了认真的事前 ...

Corporate Structure and Governance - The company established a wholly-owned subsidiary, Tianjin Weiming Biomedical Co., Ltd., to align with its strategic development needs, completing the transfer of 60.57% equity from Xiamen Weiming[1]. - The company directly holds 26.91% equity in Beijing Kexing Biological Products Co., Ltd. after the internal equity transfer from its wholly-owned subsidiary[2]. - The company ensures independent operations from its controlling shareholder, maintaining complete separation in business, personnel, assets, organization, and finance[23]. - The board of directors and supervisory board operate independently, adhering to relevant laws and regulations, ensuring effective governance[24][25]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, enhancing accountability[34]. - The company has a dedicated investor relations management system, ensuring timely and accurate information disclosure to all shareholders[28]. - The company has no related party transactions or competition with its controlling shareholder, as confirmed by a commitment letter from the shareholder[41]. - The company maintains an independent financial management system, with a dedicated finance team and separate bank accounts[43]. - The company has implemented a comprehensive internal governance structure, with various regulations updated as of November 2022[36][40]. - The company emphasizes the protection of stakeholders' rights, promoting a balanced approach to social, shareholder, and employee interests[35]. - The company has a clear organizational structure that operates independently from its controlling shareholder, ensuring no interference in business operations[43]. - The board of directors has undergone changes, with several members resigning due to term expiration[72]. - The company has received a qualified audit opinion for its 2022 financial statements, indicating areas requiring attention[32]. - The company has detailed major risks in the report, including policy risk, R&D risk, safety and environmental risk, and market competition risk[47]. - The company has implemented new strategies for stability and growth, as discussed in board meetings, highlighting a proactive approach to market challenges[158]. - The company has maintained a high attendance rate at board meetings, with key directors participating in all sessions, ensuring strong oversight[164]. Financial Performance - The company reported a total revenue of 286.53 million in the fiscal year 2022[66]. - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15% compared to RMB 1.04 billion in 2021[96]. - The net profit attributable to shareholders for 2022 was RMB 150 million, a decrease of 10% from RMB 167 million in 2021[96]. - The company's operating revenue for 2022 was ¥357,080,537.01, a decrease of 11.33% compared to ¥402,713,045.66 in 2021[109]. - The net profit attributable to shareholders for 2022 was -¥14,689,829.85, representing a decline of 105.42% from ¥271,001,671.69 in 2021[109]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥8,497,675.71, down 103.33% from ¥255,223,170.55 in the previous year[109]. - The net cash flow from operating activities was -¥54,485,087.46, a decrease of 18.41% compared to -¥46,015,293.51 in 2021[109]. - The basic and diluted earnings per share for 2022 were -¥0.0223, a drop of 105.43% from ¥0.4108 in 2021[109]. - The weighted average return on net assets was -0.62% at the end of 2022, compared to 12.03% at the end of 2021[109]. - The total assets of the company as of December 31, 2022, were RMB 3 billion, reflecting a 5% increase from RMB 2.86 billion in 2021[96]. - The total assets at the end of 2022 were ¥2,857,915,829.17, an increase of 3.69% from ¥2,756,079,609.10 at the end of 2021[109]. - The net assets attributable to shareholders at the end of 2022 were ¥2,373,520,735.73, a decrease of 0.62% from ¥2,388,210,565.58 at the end of 2021[109]. - The operating revenue after deducting unrelated income was ¥356,182,827.24 in 2022, compared to ¥397,438,686.73 in 2021[109]. - The company reported a significant decline in both revenue and profit metrics, indicating challenges in its operational performance for the year[109]. Strategic Development and R&D - In 2023, the company aims to enhance its internal management, R&D innovation, production, and marketing capabilities to drive high-quality development[5]. - The company plans to optimize its product pipeline and advance innovative drug projects through clinical trials in 2023[6]. - The company will strengthen its production management system to ensure stable operations and enhance cost-reduction measures through technological advancements[6]. - The company intends to improve brand strength and market coverage by developing flexible product policies and innovative marketing strategies[7]. - The company acknowledges the high risks associated with new drug development, including long cycles and potential market changes affecting profitability[11]. - The company will actively seek financing channels and industry resources to support its drug development and production expansion projects[12]. - The company is committed to enhancing its product offerings and technological advancements in the upcoming fiscal year[69]. - The company aims to expand its market presence and explore potential mergers and acquisitions[69]. - The company plans to expand its market presence by increasing its investment in R&D by 20% in 2023, focusing on new biopharmaceutical products[96]. - The company is actively engaging in research and development for new products[69]. - The company has established a strategic partnership with a leading technology firm to enhance its biomanufacturing capabilities[96]. - The company is focusing on expanding its market presence and developing new products in the biopharmaceutical sector[116]. - The company is committed to expanding its market presence and enhancing its product offerings through continuous research and development efforts[152]. - The company is accelerating the research and development of second-generation nerve growth factor products to strengthen its competitive edge in the market[182]. Market and Industry Trends - The biopharmaceutical industry is expected to experience high growth due to rapid economic development and increasing health awareness in China[116]. - The biopharmaceutical industry in China is expected to exceed 4 trillion yuan in market size by 2022, driven by increasing demand due to economic development and an aging population[141]. - R&D expenditure in China's pharmaceutical manufacturing industry grew from 48.847 billion yuan in 2016 to 94.244 billion yuan in 2021, with a compound annual growth rate of 14.05%[142]. - The company operates in five major biopharmaceutical segments, including interferon, nerve growth factor, CRO/CDMO, vaccines, and pharmaceutical intermediates, ensuring stable operations across all segments[146]. - The company has a diverse vaccine portfolio including COVID-19 inactivated vaccine, EV71 inactivated vaccine, and the first hepatitis A inactivated vaccine prequalified by WHO[152]. - The company’s vaccine products are positioned to meet both domestic and international health needs, showcasing its competitive edge in the biopharmaceutical sector[152]. Human Resources and Management Changes - The company experienced a significant leadership turnover, with multiple executives resigning, including the general manager and financial director[71]. - The company has seen a significant turnover in its executive team, with multiple resignations and appointments throughout 2022[79]. - The management team includes experienced professionals with backgrounds in finance and engineering, enhancing the company's strategic capabilities[119][120]. - The company has a total of 666 employees, with 34 holding a master's degree or above, and 307 with a bachelor's degree[191]. - The company has established a performance evaluation and compensation management system for its directors and senior management, ensuring transparency and alignment with company performance[133]. Compliance and Regulatory Environment - The company has faced regulatory scrutiny in the past, with warnings issued by the China Securities Regulatory Commission for information disclosure violations[129]. - The company is committed to maintaining compliance with relevant laws and regulations to ensure sustainable growth and investor confidence[130]. - The company is focused on maintaining compliance with regulatory standards and improving internal controls, as evidenced by the self-evaluation reports presented to the board[158]. Product Development and Innovation - The company’s interferon product line includes the world's first human interferon α2b aerosol spray, which fills a gap in the antiviral field[147]. - The company’s nerve growth factor product, Enjingfu, is designed for nerve injury repair and has significant biological functions for nerve regeneration[148]. - The company has launched two new products in the oncology segment, expected to contribute an additional RMB 200 million in revenue in 2023[96]. - The company has filed 16 patents since its establishment, including 2 national invention patents and 10 utility model patents, enhancing its intellectual property portfolio[178]. - The company has received recognition for its innovative products, including being named a key new product in Tianjin[147]. - The company has received a national invention patent for its "waste gas hydrogen cyanide method" production technology, which is at the world advanced level[186].